ArticleScience bulletin2023
Development and clinical application of human mesenchymal stem cell drugs.
Article in Science bulletin, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Size-Based Proteomic Signatures of Extracellular Vesicles Derived from Umbilical Cord Mesenchymal Stem Cells Fractionated by EXODUS.International journal of molecular sciences · 2026Article
- Identification and characterization of lncRNA-stemness-immune regulatory patterns.Briefings in bioinformatics · 2026Article
- Research on Injectable Hydrogel GelMA-HA-CGF Loaded with Dental Pulp Stem Cells (DPSC) for Periodontal Regeneration.ACS omega · 2026Article
- Spatiotemporal interplay between epithelial and mesenchymal cells drives human dentinogenesis.Nature communications · 2026Article
- Progress in Basic Research and Clinical Strategies for Cementum Regeneration.International dental journal · 2025Review
- Recent progress in stem cell and immune cell-based interventions for aging and age-related disorders.Frontiers in aging · 2025Review
- Enhancing regenerative medicine: the crucial role of stem cell therapy.Frontiers in neuroscience · 2024Review
- Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy.Journal of translational medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.